A recent meta-analysis by Cosmi et al., which included the Valsartan Heart Failure Trial (Val-Heft), Controlled Rosuvastatin Multinational Trial in HF (CORONA), Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF), and Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure (ATMOSPHERE), showed that the rate of all-cause mortality and HF hospitalization was higher in patients with DM than in those without, and the highest was for the patient group prescribed insulin [18–22]. The gene discussed is INS; the disease is heart failure.